Differences in the prevalence of comorbidities among sex -males are more likely to present comorbidities than females- may also partially explain the increased incidence (44 to 76% in males vs 24 to 56% in females) and mortality (55 to 64% in males vs 36 to 45% in females) observed in COVID-19 male patients [124]. These factors are expected to intersect at the regulation of ACE2: low expression levels render individuals particularly vulnerable to SARS-CoV-2, that in turn further downregulates ACE2 levels through shedding, critically affecting RAAS, bradykinin and COX-2 function. This evidence concerns the gene PTGS2 and COVID-19.